about
Aclidinium bromide for the treatment of chronic obstructive pulmonary diseaseInhaled corticosteroids with combination inhaled long-acting beta 2 -agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseIdentifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population.Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease.An analysis of the economic and patient outcome impact of an integrated COPD service in east London.Endovascular coil embolization of aneurysm neck for the treatment of ruptured intracranial aneurysm with bleb formation.Development and characterization of a long-term murine model of Streptococcus pneumoniae infection of the lower airways.Comparison of disease-severity measures within severe and very severe COPD patients: results from a nationally representative chart review and patient survey.Predictors of exacerbations in chronic obstructive pulmonary disease--results from the Bergen COPD cohort study.Reduction of exacerbation frequency in patients with COPD after participation in a comprehensive pulmonary rehabilitation program.Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective studyOne-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.Admission prevention in COPD: non-pharmacological managementSoluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.Utility of the CAT in the therapy assessment of COPD exacerbations in China.Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?Clinical factors, including All Patient Refined Diagnosis Related Group severity, as predictors of early rehospitalization after COPD exacerbation.A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary diseaseAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)A retrospective analysis to identify predictors of COPD-related rehospitalization.Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.COPD exacerbation frequency and its association with health care resource utilization and costs.Frequency and risk factors of COPD exacerbations and hospitalizations: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics: GOLDEN study).Cognitive status among patients with chronic obstructive pulmonary disease.Helping COPD patients change health behavior in order to improve their quality of life.Acute exacerbation of COPD: is it the "stroke of the lungs"?Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease.Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patientsLongitudinal changes in lung hyperinflation in COPD.Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease.Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.The Relationship Between 24-Hour Symptoms and COPD Exacerbations and Healthcare Resource Use: Results from an Observational Study (ASSESS).Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care.Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease.Impact of mild exacerbation on COPD symptoms in a Japanese cohort
P2860
Q22306019-2D7DEA49-55AA-42C4-99A2-1DF6953E2377Q24186966-D30DF8CE-18F4-49F7-9142-C6DF0C3CF79CQ24197853-F67995B5-37F3-4413-B03B-546380D6FA54Q27000043-CFBC6CA0-9C51-44CA-906A-E82720AEB738Q30370855-C21A3CD4-0BB2-4617-AE41-4EB59C75A01EQ33698659-ED3891A9-9B67-4C1A-810D-DF851E42BE2FQ33757519-F1780D7E-7015-4618-BAA0-2998CF8167ADQ33806792-7B5C83AC-5FBF-46BA-97E4-73FDF7F457B3Q33892849-E0E3AC98-7789-4096-9C61-FC3355A02AF8Q34058974-C31E27B6-1991-47F4-B55E-1C3E2BA9474BQ34273682-67E60909-7D5C-402B-AFBA-77D256CE354FQ34287563-E2AA0256-0B27-4370-85CB-7478287D03D3Q34353036-B7B382A9-A04E-45F4-9702-8CDF65197BBAQ34547587-B81AC161-DF0E-4A66-A16A-A0741FEC9D36Q34607146-8B928A63-D904-4C15-9FC1-B81E57B03749Q34609913-B16026EC-BAE4-4620-9AC2-7BAB2374548CQ35046919-0635AE68-10D6-4BFC-BA03-FAA33B7A9C7BQ35100841-DAE04C01-2025-4974-B7E2-51260F7890C6Q35117371-00DE0390-B2BF-46BC-B449-82A210F4FC35Q35184982-D08C6E30-32AE-4232-BFE7-B4B54882E3D9Q35222939-3D99EB25-DD5B-4CDB-BFF8-FCE737B456B8Q35844059-31F103F2-88E0-45E0-9BFE-E3117C5280FAQ35937943-53EC7FBD-B4E0-4F42-9364-8E942A68ADE4Q36004028-31267868-ED3C-4E0E-9EE2-AD0B21A9758BQ36188224-30B54AA6-8827-4316-94A7-7BD9C45ACABEQ36352161-FB5B5257-AA57-440D-BC0B-3B2B517AC039Q36390652-E036D4B2-BEB8-45C3-A4CC-68C6E5E26DD3Q36710134-360F5390-04C7-4184-81F4-FA41BE9C9104Q37053317-DA0F4587-799A-4A1B-946B-92D094128C1AQ37103385-DF501DA5-E77E-4E15-AA22-8B356422B7A6Q37177278-0AE99949-98C3-4B4C-AE5A-F34CB4542D50Q37186992-7EA50B02-CFE7-404C-BB20-D8DF921D1293Q37242230-BAF111D5-E83A-4A3E-8E10-702727DDE5D6Q37638752-5988CBB1-A983-4ED8-9ED2-42DE8F3E83E3Q38089196-0598E41D-75DA-4732-924A-7FF757DF80F3Q38388302-9963E6C4-7340-4BB9-81F9-0D14C4DB247BQ38894424-DCD12125-E4B0-4C65-87FA-8F7EA8D51AF1Q39422470-954DC31F-2983-4FEE-B448-A6E09CB79429Q39458622-15535D42-F8E3-44DE-A646-86BD2A43ED62Q39646728-0786D08B-B212-4A83-93B7-A5D1E9EB65A4
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Exacerbation frequency and course of COPD.
@ast
Exacerbation frequency and course of COPD.
@en
type
label
Exacerbation frequency and course of COPD.
@ast
Exacerbation frequency and course of COPD.
@en
prefLabel
Exacerbation frequency and course of COPD.
@ast
Exacerbation frequency and course of COPD.
@en
P2093
P2860
P356
P1476
Exacerbation frequency and course of COPD.
@en
P2093
Bartolome Celli
Dacheng Liu
David M G Halpin
Donald P Tashkin
Steven Kesten
P2860
P304
P356
10.2147/COPD.S34186
P407
P577
2012-09-21T00:00:00Z